Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Disease Course of Charcot-Marie-Tooth Disease Type 2 and Comorbidity—Reply

Disease Course of Charcot-Marie-Tooth Disease Type 2 and Comorbidity—Reply In reply We thank Gemignani and Marbini for their important comments on our 5-year prospective study of disease course in CMT2. First, it is unlikely that comorbidity played an important role in the neurological deterioration of our patients; comorbidity causing polyneuropathy was scarce in our cohort. Two patients had previously been treated for hypothyroid disease. During follow-up, 2 other patients developed type 2 diabetes mellitus. Second, as the authors mention, sensory complaints and abnormalities are not uncommon in CMT.1 We divided sensory complaints into positive symptoms (tingling), negative symptoms (numbness), and pain; pain was therefore separately scored. Nociceptive pain due to musculoskeletal stress may have played a role because 9 of 43 patients had shoulder, back, hip, or knee complaints. Finally, it is indeed surprising that quality of life is unchanged in these patients despite the slow progression of polyneuropathy. General quality-of-life questionnaires may not be useful to measure the main endpoints in the evaluation of patients with CMT. Back to top Article Information Correspondence: Laurien L. Teunissen, MD, PhD, St Antonius Hospital, PO Box 2500, 3430 EM Nieuwegein, the Netherlands (l.teunissen@antonius.net). References 1. Harding AEThomas PK The clinical features of hereditary motor and sensory neuropathy: types I and II. Brain 1980;103259- 280PubMedGoogle ScholarCrossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Neurology American Medical Association

Disease Course of Charcot-Marie-Tooth Disease Type 2 and Comorbidity—Reply

Disease Course of Charcot-Marie-Tooth Disease Type 2 and Comorbidity—Reply

Abstract

In reply We thank Gemignani and Marbini for their important comments on our 5-year prospective study of disease course in CMT2. First, it is unlikely that comorbidity played an important role in the neurological deterioration of our patients; comorbidity causing polyneuropathy was scarce in our cohort. Two patients had previously been treated for hypothyroid disease. During follow-up, 2 other patients developed type 2 diabetes mellitus. Second, as the authors mention, sensory complaints and...
Loading next page...
 
/lp/american-medical-association/disease-course-of-charcot-marie-tooth-disease-type-2-and-comorbidity-2r0K8h6Jqz

References (1)

Publisher
American Medical Association
Copyright
Copyright © 2004 American Medical Association. All Rights Reserved.
ISSN
0003-9942
eISSN
1538-3687
DOI
10.1001/archneur.61.9.1470-b
Publisher site
See Article on Publisher Site

Abstract

In reply We thank Gemignani and Marbini for their important comments on our 5-year prospective study of disease course in CMT2. First, it is unlikely that comorbidity played an important role in the neurological deterioration of our patients; comorbidity causing polyneuropathy was scarce in our cohort. Two patients had previously been treated for hypothyroid disease. During follow-up, 2 other patients developed type 2 diabetes mellitus. Second, as the authors mention, sensory complaints and abnormalities are not uncommon in CMT.1 We divided sensory complaints into positive symptoms (tingling), negative symptoms (numbness), and pain; pain was therefore separately scored. Nociceptive pain due to musculoskeletal stress may have played a role because 9 of 43 patients had shoulder, back, hip, or knee complaints. Finally, it is indeed surprising that quality of life is unchanged in these patients despite the slow progression of polyneuropathy. General quality-of-life questionnaires may not be useful to measure the main endpoints in the evaluation of patients with CMT. Back to top Article Information Correspondence: Laurien L. Teunissen, MD, PhD, St Antonius Hospital, PO Box 2500, 3430 EM Nieuwegein, the Netherlands (l.teunissen@antonius.net). References 1. Harding AEThomas PK The clinical features of hereditary motor and sensory neuropathy: types I and II. Brain 1980;103259- 280PubMedGoogle ScholarCrossref

Journal

Archives of NeurologyAmerican Medical Association

Published: Sep 1, 2004

Keywords: comorbidity,disease progression,motor and sensory-neuropathy type ii, hereditary

There are no references for this article.